Medical device company ResMed has acquired US-based sleep and respiratory care diagnostics software provider Somnoware for an undisclosed sum.

The software from Somnoware helps streamline physicians’ processes besides pulmonary and sleep function testing labs to diagnose and assess the respiratory and sleep care test outcomes of a patient.

It enables the scheduling of appointments, ordering of positive airway pressure (PAP) treatment equipment, tracking of PAP compliance and electronically integrating this information into a patient’s electronic health record directly.

ResMed Sleep and Respiratory Care president Lucile Blaise said: “We’re committed to driving wider adoption of Somnoware’s open and interoperable platform to help more people with OSA or COPD get the diagnoses and treatment solutions they need.”

ResMed aims to retain all the staff of Somnoware and integrate its offerings into its brand and solution ecosystem.

The company also intends to maintain the open and device-agnostic nature of Somnoware’s products.

It helps end users interoperate with several testing solutions and order treatment devices and accessories from any supplier.

Somnoware cofounder and CEO Subath Kamalasan said: “Our partnership will open new avenues to help physicians with the critical task of chronic care management.

“Together, we are committed to driving innovation and delivering solutions that improve the health of patients with sleep disorders and other chronic respiratory diseases.”

In June last year, ResMed signed an agreement to acquire German out-of-hospital software solutions provider MEDIFOX DAN in a deal valued at around $1bn.

MEDIFOX DAN, which was established in 1994, provides software solutions and services to health care and therapy providers.